Neuroscientific Biopharmaceuticals (ASX:NSB) share price jumps 9% before trading halt

It's been an interesting day on the ASX for the Australian biotech company. Here are the details

| More on:
health worker wearing personal protective equipment and gesturing stop with her hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price jumped higher this morning before becoming subject to a trading halt at lunchtime.

Before the pause in trading, the Australian biotech company's shares were exchanging hands at 31.5 cents apiece, an 8.6% leap from the open. The share price gain came after an update was released to the market prior to the opening bell.

What did Neuroscientific announce today?

Neuroscientific shares jumped on Thursday as the company provided an update on its EmtinB label.

According to Neuroscientific, "EmtinB is currently being developed as a treatment for neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve".

The announcement said EmtinB was shown to be effective in reducing "important biomarkers" associated with severe COVID-19. The study demonstrated Neuroscientific's label was effective in reducing these biomarkers by "more than 50%", versus controls.

As such, this indicates a "strong therapeutic potential" for EmtinB, "in preventing severe immune responses" from COVID-19.

Neuroscientific's hypothesis in examining EmtinB in COVID-19 was to address the "cytokine storm" that occurs with an aggressive inflammatory response in COVID-19 infection.

For example, this "storm" results in a cascade of uncontrolled inflammation in the body, which decreases a person's lung function. A rise in the incidence of these events has been purported with COVID-19, thereby leading Neuroscientific to conduct its trial.

The results obtained suggest EmtinB "is safe to administer in future work", and are an important milestone for the company.

Why are Neuroscientific shares in a trading halt?

Shares paused trading just after midday on Thursday, with the company stating it was working to "finalise an announcement detailing further information in regard to the results from pulmonary studies as announced today".

The halt will remain in place until Monday 23 August, or until the announcement is released to the market.

Neuroscientific share price snapshot

The Neuroscientific Biopharmaceuticals share price has posted a year-to-date return of 26%, extending the previous 12 months' climb of 31%.

These returns have both outpaced the S&P/ASX 200 Index (ASX: XJO)'s gain of around 25% over the last year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX was back in the black this Tuesday.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Cromwell Property, Metcash, Pilbara Minerals, and Tyro shares are falling today

Let's see why these shares are under pressure on Tuesday.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why DroneShield, Hansen, Hub24, and Paladin Energy shares are racing higher today

These shares are having a strong session. Let's find out why.

Read more »

A man in a dark blue suit walks through an airport past floor-to-ceiling windows with a Qantas plane flying in the distance
Travel Shares

Up 16% this year, does Macquarie rate Corporate Travel Management shares a buy, hold or sell?

Does the travel stock have further to fly?

Read more »

Business women working from home with stock market chart showing per cent change on her laptop screen.
Opinions

1 month until ASX earnings season begins: how I'm preparing

It’s almost reporting time. Here’s what I’m looking at.

Read more »

Smiling man with phone in wheelchair watching stocks and trends on computer
Share Market News

5 things to watch on the ASX 200 on Tuesday

A good session is expected for Aussie investors today.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Opinions

Potential buys: 2 compelling ASX shares I like

These ASX shares have an exciting future.

Read more »

Man on a laptop thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors weren't in a good mood this Monday.

Read more »